mannose/kanser

Bağlantı panoya kaydedilir

Sıralama türünü seçin

14 Sonuçlar

Mannose derivatives for killing tumor cells

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

BACKGROUND OF THE INVENTION The present invention relates generally to the field of medicine, particularly to the treatment of cancer, and more particularly, to new and useful methods for treating certain types of cancer sensitive to particular glycoside compounds. Although molecular biology has

Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

STATEMENT ACCORDING TO 37 C.F.R. .sctn.1.821(c) or (e)-SEQUENCE LISTING SUBMITTED AS TXT AND PDF FILES Pursuant to 37 C.F.R. .sctn.1.821(c) or (e), a file containing a TXT version and a PDF version of the Sequence Listing have been submitted concomitant with this application, the contents of which

Iodo-hexose compounds useful to treat cancer

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

BACKGROUND Cancer treatment regimens are frequently challenged by multi-drug resistance as tumor cells adapt in response to drug treatment. Apoptosis, a type of programmed cell death, involves a series of biochemical events that lead to changes in cell morphology and death. The apoptotic process is

Diagnostic method for gastric cancer

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

TECHNICAL FIELD The present invention relates, in general, to a method for gastric cancer diagnosis through the detection of glycan changes, a kit for gastric cancer diagnosis, and a method for detecting glycan changes in order to provide gastric cancer diagnosis information. More particularly, the

Bifunctional glycoproteins having a modified carbohydrate complement and their use in tumor-selective therapy

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

BACKGROUND OF THE INVENTION 1. Field of the Invention The invention relates to bifunctional glycoproteins having targeting protein and enzyme properties. More particularly, the invention relates to such proteins whose complements of carbohydrate residues have been modified in a manner that enhances

Synthetic glycoamines and methods for their use that affect cell adhesion, inhibit cancer cell metastasis, and induce apoptosis

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

FIELD OF THE INVENTION The present invention relates to pharmaceuticals that affect cell adhesion, inhibit cancer cell metastasis, and induce apoptosis both in vitro and in vivo. Background of the Invention Cell adhesion is one important property that differentiates multi-cellular organisms from

Mannose-receptor selective lysinylated cationic amphiphiles and a process for preparation thereof

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a national phase application under 35 U.S.C. .sctn.371 of International Application No. PCT/IN2013/000806 filed 27 Dec. 2013, which claims priority to Indian Patent Application No. 0017/DEL/2013 filed 3 Jan. 2013. The entire contents of

Mannose derivatives useful for treating pathologies associated with adherent E. coli

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

RELATED APPLICATIONS This application is the National Phase of International Application No. PCT/EP2016/068813, filed Aug. 5, 2016 which designated the U.S. and that International Application was published under PCT Article 21(2) in English, and claims priority to European Application Serial No.

Use of modified oligo-.beta.-(1,3)-glucans for treating diseases of the immune system, oligo-.beta.-(1,3)-glucan-(1,3)-mannose, oligo-.beta.-(1,3)-glucan-(1,3)-mannitol and derivatives thereof, methods for preparing them and medicaments containing them

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

The present invention relates to the use of modified oligo-.beta.-(1,3)-glucans of formula (I) or (II) below for the preparation of medicaments which are useful in treatments based on the stimulation of the immune system. The glucans, which are natural products, have long been studied and the

M6P/IGF-II receptor tumor suppressor gene

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

This application is based on and claims priority from Provisional Application Ser. No. 60/006,844, filed Nov. 16, 1995. TECHNICAL FIELD The present invention relates, in general, to a tumor suppressor and, in particular, to the mannose 6-phosphate/insulin-like growth factor-II (M6P/IGF-II) receptor

Antibodies, method of preparing same, oligosaccharides and clones for providing said antibodies, and the use of said antibodies for tumor diagnosis and therapy

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

The invention relates to novel antibodies directed against the oligosaccharide portion of glycoproteins, methods of preparing said antibodies and oligosaccharide-haptens and clones for generating these antibodies. The novel antibodies are suited for tumor diagnosis and therapy as they are capable of

Monoclonal antibodies that bind to alpha-acid glycoprotein

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

This invention relates to a monoclonal antibody and a method for the production thereof. More particularly, it relates to a monoclonal antibody specific for a .alpha..sub.1 -acid glycoprotein or specific for at least one antigenic determinant included in a sugar chain of the following formula which

Method for the analysis of N-glycans attached to immunoglobulin G from human blood plasma and its use

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

CROSS REFERENCE TO RELATED APPLICATIONS This application is the U.S. National Phase Application of PCT/HR2014/000022, filed Jun. 11, 2014, which claims priority to Croatian Patent Application No. P20130568A, filed Jun. 20, 2013, the contents of such applications being incorporated by reference

Synthetic core 2-like branched structures containing GalNAc-lewis.sup.x and Neu5Ac.alpha.2-3Gal.beta.1-3GalNAc sequences as novel ligands for selectins

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

TECHNICAL FIELD The invention relates to compounds useful in the treatment of inflammation, allergic reactions, autoimmune diseases, cancer, and similar other conditions that are cell adhesion-dependent. More specifically, the invention concerns compounds, containing GalNAc lewis.sup.x as a mucin

Facebook sayfamıza katılın

Herbal & Natural Medicine

Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı

55 dilde çalışır
Bilim destekli bitkisel kürler
Görüntüye göre bitki tanıma
Etkileşimli GPS haritası - bölgedeki bitkileri etiketleyin (yakında)
Aramanızla ilgili bilimsel yayınları okuyun
Şifalı bitkileri etkilerine göre arayın
İlgi alanlarınızı düzenleyin ve haber araştırmaları, klinik denemeler ve patentlerle güncel kalın

Bir belirti veya hastalık yazın ve yardımcı olabilecek bitkiler hakkında bilgi edinin, bir bitki yazın ve karşı kullanıldığı hastalıkları ve semptomları görün.
* Tüm bilgiler yayınlanmış bilimsel araştırmalara dayanmaktadır